Annual Meeting – Clinical Advancements Update

Advanced Epigenetic Technology

December 15, 2016

Todays Agenda for Zenith Capital Corp.

1. Corporate Profile & Structure
2. Epigenetic Mechanism
3. Prostate Cancer Rationale
4. Phase 1 Details & Early Results
5. Enzalutamide Combination Trial – Phase 1b
6. Next Steps
7. Intellectual Property

CONTACT: Donald J. McCaffrey, Chairman, President & CEO
Suite 300, 4820 Richard Road S.W. Calgary, AB, Canada T3E 6L1
Tel: (403) 254-9252, Fax:(403) 256-8495, http://www.zenithepigenetics.com

Share Structure Profile

Founded	Corporate spin out from Resverlogix in June 2013
Status	Unlisted Possible US market IPO when conditions permit
Cash Raised 2014-2016	Approx. US$44MM @ $1.00 USD per share
Enterprise Value est.	$250 MM
Shares Outstanding	125.2 MM 134.0 MM fully diluted
Cash Burn	$2 MM per quarter - Current

Post July 31, 2016 Corporate Structure

POST-REORGANIZATION JULY 31, 2016 STRUCTURE



Historical Timeline & Strategic Progression

Company formation

Spun out of Resverlogix to focus on oncology/auto-immune

FDA approved IND for ZEN-3365

Top investigators & institutions recruited for Phase 1

Jul 2014

Challenges

Prior to the Phase 1 launch , overlapping IP published by another group,

ZEN-3365 discontinued

Oct 2014

Change of plans

ZEN-3694 selected as DC, superior properties, mutiple back ups, IP published

May 2015

Focused clinical strategy

IND accepted

MSKCC/UCSF selected as lead clincial sites (mCRPC)

Dec 2015

Financing

Raised $25M

Mar 2016

First patient dosed

Jun 2016

Biology Expansion

Immuno-Oncology

TNBC, NSCLC, ER+ Breast, next indications

Ongoing

Epigenetics Mechanism

- 1. Corporate Profile & Structure
- **2. Epigenetic Mechanism**
- 3. Prostate Cancer Rationale
- 4. Phase 1 Details & Early Results
- 5. Enzalutamide Combination Trial – Phase 1b
- 6. Next Steps
- 7. Intellectual Property

Epigenetics, the Mechanism Behind Our Approach



Zenith's BRD4 Targets Resistance Mechanisms

Signaling inhibitors
- γ-secretase (leukemia)
- Smoothened (medulloblastoma)
- RAF (melanoma)

Hormone-deprivation therapies
- Androgen (prostate cancer)
- Estrogen (breast cancer)



Antibody-based therapies
- Rituximab (lymphoma)



Super-enhancer cluster

BRD4

Chemotherapies
- Tamoxifen (breast cancer)
- Everolimus (breast cancer)

Cancers Escape Mechanism

Resistance mechanism involving BRD4 (treatment with BETi resensitizes cancers to these therapies)

Resistance to several standard of care treatments does not impede sensitivity to BETi

Prostate Cancer Rational

- 1. Corporate Profile & Structure
- 2. Epigenetic Mechanism
- **3. Prostate Cancer Rationale**
- 4. Phase 1 Details & Early Results
- 5. Enzalutamide Combination Trial – Phase 1b
- 6. Next Steps
- 7. Intellectual Property

Unmet Need in Metastatic Prostate Cancer (mCRPC)

Current Market and Unmet Need

- ~135,000 annual mCRPC patients in the US/EU alone – majority receive enzalutamide or abiraterone as first-line treatment
- **Over $4B in sales in 2015** for first-line enzalutamide and abiraterone
- Patients become resistant to these therapies, no effective second-line therapy yet
- Continuing high mortality rate in resistant mCRPC (50% 1 year survival, 28% in 5 years)

Opportunity for ZEN-3694

- Second-line single-agent treatment
  - key opinion leaders agree that there is no effective second-line treatment
  - ~60,000 second-line treatment eligible patients in US/EU alone
- Expand into first-line treatment in combination with enzalutamide or abiraterone

Prostate Cancer Epidemiology & Market

	US/EU Prevalence (2015)	5 Year Survival Rate	Japan Prevalence	Korea Prevalence	China Prevalence
mCRPC	~ 134,000	28%	~26,000	~3300	~16,000



The global prostate cancer WW market is expected to reach $11B by 2019, driven by Zytiga and Xtandi.

ZEN-3694 Potential in Patients Developing mCRPC Resistance to Enzalutamide

ZEN-3694 works down stream of current therapies

ZEN-3694 works where resistance to existing lead drugs, like Enzalutamide, has evolved

The combination of ZEN-3694 & todays top medications show strong synergizes and expected reduction to resistance





12

Potential Resistance Pathways in CRPC in response to Enzalutamide and/or Abiraterone



ZEN-3694 shows good efficacy in different CRPC models that are resistant to AR antagonists

Phase 1 Details & Early Results

- 1. Corporate Profile & Structure
- 2. Epigenetic Mechanism
- 3. Prostate Cancer Rationale
- **4. Phase 1 Details & Early Results**
- 5. Enzalutamide Combination Trial – Phase 1b
- 6. Next Steps
- 7. Intellectual Property

Zenith's Principal Investigators

Name	Institution	Comments
Eric Small, MD *Chief, Dept. of Medicine* **Rahul Aggarwal, MD** *Developmental Therapeutics Specialist, Genitourinary Oncologist*	University of California, San Francisco (UCSF)	Developed abiraterone - #2 CRPC drug, owned by J&J.
Howard Scher, MD *Chief, Genitourinary Oncology* **Wassim Abida, MD, PhD** *Medical Oncologist*	Memorial Sloane Kettering Cancer Center (MSKCC)	Developed enzalutamide - #1 CRPC drug, now owned by Pfizer. Developing ARN-509 for J&J
Joshi Alumkal, MD *Associate Professor*	Oregon Health Sciences University (OHSU)	Expert in epigenetics in prostate cancer research
Allan Pantuck, MD *Professor, Dept. of Urology*	University of California Los Angeles (UCLA)	Involved in enzalutamide and provenge development
Elizabeth Heath, MD *Professor, Dept. Hematology/Oncology*	Karmanos (Wayne State)	Genitourinary oncology specialist
Tom Fleming, MD *Oncologist*	Virginia Oncology Associates	Community site for high enrollment

Castration-resistant Prostate Cancer (CRPC) Treatment Algorithm



Medical need for targeting patients resistant to AR targeted agents;
Need for targeting downstream AR signaling and alternate resistance pathways

3 + 3 Dose Escalation Design



Note: MTD (Maximum tolerated dose) is the highest dose with ≤ 1 DLT in 6 patients. DLT is Dose Limiting Toxicity

ZEN-3694 Phase 1 Study Endpoints

Primary

- Safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ZEN-3694

Secondary

- Pharmacokinetics (PK)
- Preliminary clinical activity
  - PCWG2 Criteria: PSA response rate, Radiographic response rate, PFS
  - Circulating Tumor Cell (CTC) response rate

Phase 1 Status

ZEN-3694 single-agent study ongoing

- Maximum Tolerated Dose (MTD) confirmation
- Good PK, exposures reach IC_{50} cell proliferation values
- **Target modulation shown**
- On-target safety profile
- Longest patient on drug now beyond 4 months
- Intermittent dosing schedule cohorts may be initiated in Q1/17 for recommended Phase 2 dose (in discussion)

Target Modulation Measured in Clinic



Robust target modulation for 24h

Enzalutamide Combination Trial – Phase 1b

- 1. Corporate Profile & Structure
- 2. Epigenetic Mechanism
- 3. Prostate Cancer Rationale
- 4. Phase 1 Details & Early Results
- **5. Enzalutamide Combination Trial – Phase 1b**
- 6. Next Steps
- 7. Intellectual Property

ZEN-3694 Synergizes With Enzalutamide & ARN-509



uM ZEN3694	IC50 uM of Enzalutamide in VCAP + 0.1 nM R1881
0	4.98
0.1	0.58
1	0.09
10	<0.09



uM ZEN3694	IC50 uM of ARN-509 in VCAP + 0.1 nM R1881
0	2.24
0.1	0.36
1	0.02
10	<0.02

VCAP curve shift: Enzalutamide and ARN-509 sensitive, ZEN003694 highly synergistic

ZEN-3694 Phase 1b Study Design

Phase 1b, open label, combination, 3x3 dose escalation/confirmation



ZEN-3694 Phase 1b Study Endpoints

Primary

- Safety, tolerability, MTD, and RP2D of ZEN-3694 in combination with enzalutamide

Secondary

- Pharmacokinetics (PK) af ZEN-3694 and enzalutamide when given in combination
- Preliminary clinical activity
  - PCWG2 Criteria: PSA response rate, Radiographic response rate, Median PFS
  - Circulating Tumor Cell (CTC) response rate

Next Steps

- 1. Corporate Profile & Structure
- 2. Epigenetic Mechanism
- 3. Prostate Cancer Rationale
- 4. Phase 1 Details & Early Results
- 5. Enzalutamide Combination Trial – Phase 1b
- **6. Next Steps**
- 7. Intellectual Property

BET Inhibitors Potential as Combination Agents



BRD4 target, is directly involved in the resistance mechanisms of several types of anti-cancer therapies

ZEN-3694 Synergizes With Several Standard of Care Cancer Drugs



Indication		Cell line (mutation)
NSCLC	▲	H1975 (EGFR L858R T790M)
	●	H820 (EGFR T790M)
	■	H2228 (ALK)
AR+ Breast	◆	MDA-MB-453
ER+ Breast	■	MCF-7 (ER+)
	▼	ZR-75-1 (ER+)
TNBC	●	HCC1937 (BRCA1)
Melanoma	✖	C32 (BRAF V600E)
	⬢	A375 (BRAF)
DLBCL	⬢	CARNAVAL (MYC/BCL2)
	●	OCI-LY18 (MYC/BCL2)
	◆	NU-DUL-1
	■	OCI-LY3 (A20)
Prostate	▼	VCAP (AR AMP/AR-V7)
AML	■	MV4-11 (MLL-AF4/FLT3-ITD)
	●	OCI-AML2 (DNMT3A/MLL)
	▼	OCI-AML3 (DNMT3A/NPM1)

Potential Resistance Pathways in TNBC in Response to Chemotherapy

AC-T

TNBC

Resistance mechanism



EMT

BETi down Regulates Several key players Twist targets (Wnt5a)

WNT signaling

BETi modulates WNT pathways

XBP1s driven hypoxia



BETi downregulates XBP1s

Rationale for ZEN-3694 to show activity in different TNBC models that are resistant to chemotherapy

ZEN-3694 is Synergistic With Paclitaxel in Triple-negative Breast Cancer Models



Treatment Groups	TGI
EA006 (Vehicle)	0%
ZEN-3694 50 mg/kg qd	46%
ZEN-3694 100 mg/kg qd	64%
OTX-015 100 mg/kg qd	54%
Paclitaxel 15 mg/kg IP	52%
Paclitaxel 15 mg/kg IP + ZEN-3694 50 mg/kg qd	101%



- Combination regimen is well tolerated
- ZEN-3694 is more potent than OTX at equivalent dose
- ZEN-3694 is synergistic in combo with Paclitaxel (5/12 regressed tumors)

Intellectual Property

- 1. Corporate Profile & Structure
- 2. Epigenetic Mechanism
- 3. Prostate Cancer Rationale
- 4. Phase 1 Details & Early Results
- 5. Enzalutamide Combination Trial – Phase 1b
- 6. Next Steps
- **7. Intellectual Property**

Intellectual Property: Status Update

Zenith Epigenetics Ltd. owns numerous patent families, including three issued US patents and 60 pending applications. The portfolio includes a number of US applications and world-wide equivalents.

Composition Patents						
Zenith Reference Number	Provisional Patent Application	Patent Application	Publication	National Stage	Examination	Issuance
22981-36						
22981-37						2x
22981-38						
22981-39						
22981-40						
22981-41						
22981-45						
22981-46				National phase mid 2017		
22981-47				National phase mid 2017		
22981-49				National phase mid 2017		
22981-50				National phase mid 2017		
22981-51				National phase mid 2017		
22981-57		Convert mid Dec.2016				

ZEN-3694 Patent Application



How can you determine the true potential of a new clinical drug candidate in oncology?

There are hundreds of biotech company's with potential drug candidates

Drug candidates require 3rd party Principle Investigators (PI's) to act as independent clinical investigators

The best oncology units and principle investigators in the United States are highly sought after

Zenith's cutting edge technology has attracted the top two U.S. PI's in prostate cancer research as well as the Prostate Cancer Clinical Trials Consortium (PCCTC)

Zenith has confirmed PI's
-Dr. Eric Small - Univ. of California, San Francisco
-Dr. Howard Scher at Memorial-Sloan Kettering , NY

Both Dr's Small & Scher where involved in the developed of the top 2 current prostate drugs in use, abiraterone & enzalutamide respectively

Four of the last five FDA approved prostate drugs have come from the PCCTC which is highly selective and only champions the most promising drugs

Annual Meeting – Clinical Advancements Update

Advanced Epigenetic Technology

December 15, 2016